Research Article

Clinical Effect of Revascularization Strategies and Pharmacologic Treatment on Long-Term Results in Patients with Advanced Peripheral Artery Disease with TASC C and D Femoropopliteal Lesions

Table 1

Baseline demographics and characteristics associated with intervention.

CharacteristicTotal population (n = 187)EVT group (n = 94)Bypass group (n = 93) value

Age (years)75.1 ± 11.975.8 ± 13.474.4 ± 10.30.424
BMI23.4 ± 4.424 ± 3.722.8 ± 5.00.079
SBP137.1 ± 24.1137.1 ± 24.1137.1 ± 24.20.988
Gender (female)52 (27.8)26 (27.7)26 (28.0)0.964
Lesion site (left)91 (48.7)45 (47.9)46 (49.5)0.828
Baseline CAD71 (38)34 (36.2)37 (39.8)0.611
ESRD (regular dialysis)66 (35.6)36 (38.3)30 (32.3)0.388
DM112 (59.9)61 (64.9)51 (54.8)0.161
Hypertension154 (82.4)76 (80.9)78 (83.9)0.588
Hyperlipidemia51 (27.3)25 (26.6)26 (28.0)0.321
Baseline CVA24 (12.8)15 (16)9 (9.7)0.199
Smoking75 (40.3)35 (37.6)40 (43.0)0.455
Cellulitis on presentation145 (77.5)74 (78.7)71 (76.3)0.697
Atrial fibrillation14 (7.5)9 (9.6)5 (5.4)0.275
Baseline ABI0.52 ± 0.130.51 ± 0.110.53 ± 0.160.473
Calcification75 (43.6)36 (42.4)39 (44.8)0.744
Retinopathy28 (15)18 (19.1)10 (10.8)0.108
Neuropathy49 (26.2)29 (30.9)20 (21.5)0.146
Rutherford classification0.757
Stage III17 (9.1)10 (10.6)7 (7.5)
Stage IV41 (21.9)20 (21.3)21 (22.6)
Stage V plus VI129 (69)64 (68.1)65 (66.9)
hsCRP (mg/L)4.85 ± 5.234.45 ± 4.995.28 ± 5.490.297
HA1c (%)7.51 ± 1.577.57 ± 1.577.43 ± 1.590.659
Concomitant medications
OHA alone65 (37.8)27 (31.8)38 (43.7)0.107
Insulin alone55 (29.4)30 (31.9)25 (26.9)0.450

ABI: ankle brachial index; BMI: body mass index; SBP: systolic blood pressure; CAD: coronary artery disease; CVA: cerebral vascular accident; DM: diabetes mellitus; ESRD: end-stage renal disease; EVT, endovascular therapy; hsCRP: high-sensitivity C-reactive protein; HA1c: hemoglobin A1c; OHA, oral hypoglycemic agent.